

### REMARKS

This communication is responsive to the Office Action mailed on November 16, 2006, in which all pending claims 28-48 were rejected on the basis of obviousness-type double patenting over certain claims in the following patents and applications:


1. Alferness U.S. Patent 6,375,608;
2. Alferness U.S. Patent 6,893,392 in view of Lekholm U.S. Patent 5,042,463;
3. Alferness U.S. Patent 6,544,168 in view of Lekholm U.S. Patent 5,042,463;
4. Alferness U.S. Patent 6,165,122 in view of Lekholm U.S. Patent 5,042,463;
5. Alferness U.S. Patent 6,077,218 in view of Lekholm U.S. Patent 5,042,463;
6. Alferness U.S. Patent 5,702,343 in view of Lekholm U.S. Patent 5,042,463;
7. Alferness U.S. Application No. 10/672,227 in view of Lekholm U.S. Patent 5,042,463; and
8. Alferness U.S. Application No. 10/810,099 in view of Lekholm U.S. Patent 5,042,463.

A Terminal Disclaimer over U.S. Patent No. 6,375,608 was filed in this application on September 26, 2003. Terminal disclaimers over the other U.S. applications and patents commonly-assigned to Acorn Cardiovascular are enclosed. Withdrawal of the rejections and allowance of all pending claims 28-48 are requested.

Respectfully submitted,

FAEGRE & BENSON LLP

By:

  
Walter C. Linder, Reg. No. 31,707  
612/766-8801  
Customer No.: 25764

Dated: January 30, 2007